Freestone Grove Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Freestone Grove Partners’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$43	–	1101
2026 Q1	$43	Buy	+2	New	+$28	﹤0.01%	922

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Freestone Grove Partners's DAWN Position: Q2 2026 in Review

Freestone Grove Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 2 shares — an estimated $43 sold.

Freestone Grove Partners first reported a position in DAWN in Q1 2026 and held it in 1 quarter. The position peaked at $43 in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Freestone Grove Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Freestone Grove Partners sold 2 Day One Biopharmaceuticals shares in Q2 2026, an estimated $43.
Freestone Grove Partners first reported a position in Day One Biopharmaceuticals in Q1 2026 and held it in 1 quarter.
Freestone Grove Partners's Day One Biopharmaceuticals position peaked at $43 in Q1 2026.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.